Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-04-27

AUTHORS

Fatemeh Kalalinia, Fatemeh Elahian, Javad Behravan

ABSTRACT

PurposeABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines.MethodsThe cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay.ResultsTPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX.ConclusionThe results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2. More... »

PAGES

321-330

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9

DOI

http://dx.doi.org/10.1007/s00432-010-0893-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015219571

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20422426


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily G, Member 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP-Binding Cassette Transporters", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Celecoxib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flow Cytometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Enzymologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetradecanoylphorbol Acetate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalalinia", 
        "givenName": "Fatemeh", 
        "id": "sg:person.01354672317.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elahian", 
        "givenName": "Fatemeh", 
        "id": "sg:person.01322665107.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322665107.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Behravan", 
        "givenName": "Javad", 
        "id": "sg:person.01245756105.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245756105.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1202218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036542534", 
          "https://doi.org/10.1038/sj.onc.1202218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2867-5-30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003230076", 
          "https://doi.org/10.1186/1475-2867-5-30"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1206938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036684086", 
          "https://doi.org/10.1038/sj.onc.1206938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/aapsj070112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032127936", 
          "https://doi.org/10.1208/aapsj070112"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-04-27", 
    "datePublishedReg": "2010-04-27", 
    "description": "PurposeABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines.MethodsThe cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay.ResultsTPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX.ConclusionThe results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-010-0893-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "137"
      }
    ], 
    "keywords": [
      "breast cancer cell lines", 
      "ABCG2 activity", 
      "cancer cell lines", 
      "COX-2", 
      "cell lines", 
      "mitoxantrone efflux", 
      "multidrug resistance", 
      "use of celecoxib", 
      "long-term treatment", 
      "efflux transporter ABCG2", 
      "cyclooxygenase-2 expression", 
      "COX-2 inducer", 
      "multidrug resistance phenotype", 
      "adjuvant therapy", 
      "greater stimulatory effect", 
      "cyclooxygenase-2", 
      "little inhibitory activity", 
      "MethodsThe cytotoxicity", 
      "probable causal link", 
      "effect of TPA", 
      "drug efflux", 
      "chemotherapeutic drugs", 
      "stimulatory effect", 
      "cancer treatment", 
      "celecoxib", 
      "MTT assay", 
      "transporter ABCG2", 
      "ABCG2", 
      "potential role", 
      "anticancer drugs", 
      "inhibitory activity", 
      "resistance phenotype", 
      "efflux", 
      "drugs", 
      "potential link", 
      "treatment", 
      "wide spectrum", 
      "TPA", 
      "causal link", 
      "patients", 
      "activity", 
      "therapy", 
      "tumors", 
      "cancer", 
      "inhibitors", 
      "role", 
      "cytotoxicity", 
      "inducer", 
      "phenotype", 
      "assays", 
      "effect", 
      "resistance", 
      "group", 
      "aim", 
      "years", 
      "expression", 
      "lines", 
      "study", 
      "regulation", 
      "recent years", 
      "use", 
      "development", 
      "members", 
      "link", 
      "tendency", 
      "results", 
      "growth", 
      "exploring", 
      "spectra", 
      "PurposeABCG2", 
      "flow cytometric mitoxantrone efflux", 
      "cytometric mitoxantrone efflux", 
      "ResultsTPA", 
      "MCF7-MX", 
      "drug efflux transporter ABCG2"
    ], 
    "name": "Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines", 
    "pagination": "321-330", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015219571"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-010-0893-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20422426"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-010-0893-9", 
      "https://app.dimensions.ai/details/publication/pub.1015219571"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-010-0893-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'


 

This table displays all metadata directly associated to this object as RDF triples.

252 TRIPLES      22 PREDICATES      126 URIs      114 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-010-0893-9 schema:about N2f58dec8ed6141a8bcc8b12bb26d1289
2 N3ac2468bba444539b9cbd06468a46975
3 N473e1ed9541546429c8ef99a8f4a7466
4 N49b325d6829d44ae8b1f1eb552285a0e
5 N5aae3501acd24b999b6825adfdda405f
6 N6632e82d05ae49ad86c1d20deb47cd15
7 N719b50227c6547e7b37d76c35f9cceae
8 N77bd4ac693f043ccb46e9ec41b36daa0
9 N78ad9e7969b24ab4807f5ec4668e8e0f
10 N8441318f271544c49128e0d39e4df3ca
11 N8fbaecf2771b4282bc082f44e034ae50
12 N93de89a885e04a6281e60ca882bbf3ea
13 Na287136ae53846a6851fb1838973cbf6
14 Nbf7a749975e7422ea8a2b8610206e65d
15 Nbf8da505f0fc4d24808645254b126623
16 Nd15b9e83bf1d426f9328891a3a3ff7ad
17 Nd2bebf691e3449f5ad646e7adc7ceee9
18 Ndde20ca666194977a73bbd47350f985f
19 Ne328c6ac55a645be8365c3f874304dae
20 Ne6e4d127a82b4154a1239ac7b0ad1af4
21 Nf89f1aed4b3345c6a394a0875e934df1
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author Nc9b9c3ffd8c14575a60f1adc228182a3
25 schema:citation sg:pub.10.1038/sj.onc.1202218
26 sg:pub.10.1038/sj.onc.1206938
27 sg:pub.10.1186/1475-2867-5-30
28 sg:pub.10.1208/aapsj070112
29 schema:datePublished 2010-04-27
30 schema:datePublishedReg 2010-04-27
31 schema:description PurposeABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines.MethodsThe cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay.ResultsTPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX.ConclusionThe results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N272d7d8f84e64d5584f38f3f2d6d9fe0
36 N6ab7b76afaee4bceb58337c899d22738
37 sg:journal.1313647
38 schema:keywords ABCG2
39 ABCG2 activity
40 COX-2
41 COX-2 inducer
42 MCF7-MX
43 MTT assay
44 MethodsThe cytotoxicity
45 PurposeABCG2
46 ResultsTPA
47 TPA
48 activity
49 adjuvant therapy
50 aim
51 anticancer drugs
52 assays
53 breast cancer cell lines
54 cancer
55 cancer cell lines
56 cancer treatment
57 causal link
58 celecoxib
59 cell lines
60 chemotherapeutic drugs
61 cyclooxygenase-2
62 cyclooxygenase-2 expression
63 cytometric mitoxantrone efflux
64 cytotoxicity
65 development
66 drug efflux
67 drug efflux transporter ABCG2
68 drugs
69 effect
70 effect of TPA
71 efflux
72 efflux transporter ABCG2
73 exploring
74 expression
75 flow cytometric mitoxantrone efflux
76 greater stimulatory effect
77 group
78 growth
79 inducer
80 inhibitors
81 inhibitory activity
82 lines
83 link
84 little inhibitory activity
85 long-term treatment
86 members
87 mitoxantrone efflux
88 multidrug resistance
89 multidrug resistance phenotype
90 patients
91 phenotype
92 potential link
93 potential role
94 probable causal link
95 recent years
96 regulation
97 resistance
98 resistance phenotype
99 results
100 role
101 spectra
102 stimulatory effect
103 study
104 tendency
105 therapy
106 transporter ABCG2
107 treatment
108 tumors
109 use
110 use of celecoxib
111 wide spectrum
112 years
113 schema:name Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines
114 schema:pagination 321-330
115 schema:productId N3dd1616b21b042d5aff473ce1504bafa
116 N7bb82bbbc9c7441eb7a30bc365181430
117 Nbfb07ac2f29e4aa2866dd3cac76f49af
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015219571
119 https://doi.org/10.1007/s00432-010-0893-9
120 schema:sdDatePublished 2022-01-01T18:23
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N913de551593247e5a8754ed70145cfe9
123 schema:url https://doi.org/10.1007/s00432-010-0893-9
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N272d7d8f84e64d5584f38f3f2d6d9fe0 schema:issueNumber 2
128 rdf:type schema:PublicationIssue
129 N2f58dec8ed6141a8bcc8b12bb26d1289 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Cell Proliferation
131 rdf:type schema:DefinedTerm
132 N3ac2468bba444539b9cbd06468a46975 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 N3dd1616b21b042d5aff473ce1504bafa schema:name pubmed_id
136 schema:value 20422426
137 rdf:type schema:PropertyValue
138 N473e1ed9541546429c8ef99a8f4a7466 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name ATP Binding Cassette Transporter, Subfamily G, Member 2
140 rdf:type schema:DefinedTerm
141 N49b325d6829d44ae8b1f1eb552285a0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name ATP-Binding Cassette Transporters
143 rdf:type schema:DefinedTerm
144 N5aae3501acd24b999b6825adfdda405f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Drug Resistance, Neoplasm
146 rdf:type schema:DefinedTerm
147 N6632e82d05ae49ad86c1d20deb47cd15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Antineoplastic Agents
149 rdf:type schema:DefinedTerm
150 N6ab7b76afaee4bceb58337c899d22738 schema:volumeNumber 137
151 rdf:type schema:PublicationVolume
152 N6fa75727b16543cb9196968815f7918a rdf:first sg:person.01245756105.18
153 rdf:rest rdf:nil
154 N719b50227c6547e7b37d76c35f9cceae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Gene Expression Regulation, Enzymologic
156 rdf:type schema:DefinedTerm
157 N77bd4ac693f043ccb46e9ec41b36daa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cell Line, Tumor
159 rdf:type schema:DefinedTerm
160 N78ad9e7969b24ab4807f5ec4668e8e0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Tetradecanoylphorbol Acetate
162 rdf:type schema:DefinedTerm
163 N7bb82bbbc9c7441eb7a30bc365181430 schema:name doi
164 schema:value 10.1007/s00432-010-0893-9
165 rdf:type schema:PropertyValue
166 N8441318f271544c49128e0d39e4df3ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Drug Resistance, Multiple
168 rdf:type schema:DefinedTerm
169 N8fbaecf2771b4282bc082f44e034ae50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Cyclooxygenase 2
171 rdf:type schema:DefinedTerm
172 N913de551593247e5a8754ed70145cfe9 schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 N93de89a885e04a6281e60ca882bbf3ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Breast Neoplasms
176 rdf:type schema:DefinedTerm
177 Na287136ae53846a6851fb1838973cbf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Flow Cytometry
179 rdf:type schema:DefinedTerm
180 Nbf7a749975e7422ea8a2b8610206e65d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Cyclooxygenase 2 Inhibitors
182 rdf:type schema:DefinedTerm
183 Nbf8da505f0fc4d24808645254b126623 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Sulfonamides
185 rdf:type schema:DefinedTerm
186 Nbfb07ac2f29e4aa2866dd3cac76f49af schema:name dimensions_id
187 schema:value pub.1015219571
188 rdf:type schema:PropertyValue
189 Nc9b9c3ffd8c14575a60f1adc228182a3 rdf:first sg:person.01354672317.51
190 rdf:rest Nd3d963cf8ce648509a9cf10266df1a4a
191 Nd15b9e83bf1d426f9328891a3a3ff7ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Celecoxib
193 rdf:type schema:DefinedTerm
194 Nd2bebf691e3449f5ad646e7adc7ceee9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Female
196 rdf:type schema:DefinedTerm
197 Nd3d963cf8ce648509a9cf10266df1a4a rdf:first sg:person.01322665107.11
198 rdf:rest N6fa75727b16543cb9196968815f7918a
199 Ndde20ca666194977a73bbd47350f985f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Pyrazoles
201 rdf:type schema:DefinedTerm
202 Ne328c6ac55a645be8365c3f874304dae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Neoplasm Proteins
204 rdf:type schema:DefinedTerm
205 Ne6e4d127a82b4154a1239ac7b0ad1af4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Mitoxantrone
207 rdf:type schema:DefinedTerm
208 Nf89f1aed4b3345c6a394a0875e934df1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Gene Expression Regulation, Neoplastic
210 rdf:type schema:DefinedTerm
211 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
212 schema:name Medical and Health Sciences
213 rdf:type schema:DefinedTerm
214 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
215 schema:name Oncology and Carcinogenesis
216 rdf:type schema:DefinedTerm
217 sg:journal.1313647 schema:issn 0171-5216
218 1432-1335
219 schema:name Journal of Cancer Research and Clinical Oncology
220 schema:publisher Springer Nature
221 rdf:type schema:Periodical
222 sg:person.01245756105.18 schema:affiliation grid-institutes:grid.411583.a
223 schema:familyName Behravan
224 schema:givenName Javad
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245756105.18
226 rdf:type schema:Person
227 sg:person.01322665107.11 schema:affiliation grid-institutes:grid.411583.a
228 schema:familyName Elahian
229 schema:givenName Fatemeh
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322665107.11
231 rdf:type schema:Person
232 sg:person.01354672317.51 schema:affiliation grid-institutes:grid.411583.a
233 schema:familyName Kalalinia
234 schema:givenName Fatemeh
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51
236 rdf:type schema:Person
237 sg:pub.10.1038/sj.onc.1202218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036542534
238 https://doi.org/10.1038/sj.onc.1202218
239 rdf:type schema:CreativeWork
240 sg:pub.10.1038/sj.onc.1206938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036684086
241 https://doi.org/10.1038/sj.onc.1206938
242 rdf:type schema:CreativeWork
243 sg:pub.10.1186/1475-2867-5-30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003230076
244 https://doi.org/10.1186/1475-2867-5-30
245 rdf:type schema:CreativeWork
246 sg:pub.10.1208/aapsj070112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032127936
247 https://doi.org/10.1208/aapsj070112
248 rdf:type schema:CreativeWork
249 grid-institutes:grid.411583.a schema:alternateName Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran
250 schema:name Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
251 Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran
252 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...